EXOSOMES MARKET Size and trends

Exosomes Market Size and Trends

The Global Exosomes Market is estimated to be valued at USD 222.1 Mn in 2025 and is expected to reach USD 1,284.1 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 28.5% from 2025 to 2032.

Key Takeaways of the Exosomes Market:

• In terms of product & service, the kits & reagents segment is expected to contribute the highest share of the market with 45.1% in 2025.
• In terms of indication, the cancer segment is expected to contribute the highest share of the market with 34.3% in 2025.
• In terms of application, the biomarkers segment is expected to contribute the highest share of the market with 26.2% in 2025.
• North America is expected to top the global market with 38.3% share, followed by Asia Pacific with 26.6% share in 2025.

Market Overview:

The growth in the market is attributed to factors such as rising focus on liquid biopsy in disease diagnosis and increasing adoption of exosome therapeutics. Moreover, increasing healthcare expenditure in emerging nations is further contributing to the market growth. Applications of exosomes in drug delivery and vaccine development would provide lucrative opportunities in the upcoming years. However, lack of awareness about the clinical benefits of exosomes among people remains a challenge. Also, technical challenges in isolating exosomes may hamper the market growth during the forecast period.

To learn more about this report, Request sample copy

Key Developments:

• In December 2024, BrainStorm Cell Therapeutics Inc., a biotechnology company, announced a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application covering proprietary exosome technology. The patent details exosomes derived from mesenchymal stem cells secreting neurotrophic factors (MSC-NTF), produced via a unique process.
• In January 2024, EXO Biologics, a Belgium-based biotech company specializing in exosome-based biopharmaceuticals for rare diseases, introduced ExoXpert, a contract development and manufacturing organization (CDMO) dedicated to exosome production
• In October 2023, Cytiva, a global leader in biopharmaceutical solutions, partnered with RoosterBio, Inc., a cell and exosome engineering firm, to develop a scalable purification process for mass-producing exosomes, addressing key challenges in therapeutic and gene therapy applications.
• In January 2023, Sartorius, a life science research leader, and RoosterBio expanded their collaboration to enhance exosome production processes by tackling purification challenges and advancing analytical techniques for improved quality control, yield, and therapeutic potency.

Top Strategies Followed by Global Exosomes Market Players

• Established Players: Leading companies are heavily investing in R&D to innovate and enhance exosome-based products
  • For instance, in April 2024, EXO Biologics secured up to USD 16.5 million in Series A funding to advance their exosome therapeutic development and clinical supply
  • Collaborations are pivotal for market expansion and technological advancement. In May 2024, ExoXpert partnered with Neucore Bio to leverage ExoXpert's platform for advanced exosome loading, aiming to enhance therapeutic applications.
• Mid-level players, such as Kimera Labs, focus on delivering cost-effective solutions that target price-sensitive consumers. By offering high-quality exosome products at competitive prices, they aim to capture a larger market share. Collaborations are also key; for example, partnerships between mid-level firms and research institutions have been established to boost technology and production capabilities, enhancing their market presence
• Small-scale players often target niche markets with unique features or innovative products. For instance, startups like AIVITA Biomedical specialize in personalized exosome therapies for specific conditions, allowing them to carve out a distinct market segment. These companies frequently adopt cutting-edge technologies, such as advanced exosome isolation methods, to remain competitive. Local alliances with regional manufacturers also help these players gain market entry and visibility, fostering growth in emerging markets.

Emerging Startups - Exosomes Industry Ecosystem

• Innovative Technologies: Startups like Xollent are developing advanced exosome-based therapeutics. Xollent utilizes exosomes derived from cardiac stem cells to stimulate cardiac regeneration following myocardial infarction, showcasing the therapeutic potential of exosome technology. These innovations are poised to significantly influence market dynamics by introducing novel treatment modalities, potentially improving patient outcomes and expanding the therapeutic applications of exosomes.
• Sustainable Solutions: Eco-friendly startups, such as Exosome Sciences, focus on sustainability by developing biodegradable exosome-based products. Their initiatives contribute to reducing the industry’s environmental footprint, aligning with global sustainability trends.
• Market Contribution: In June 2020, Sarepta Therapeutics and Codiak BioSciences have announced a global research agreement to develop engineered exosome therapeutics for delivering gene therapy, gene editing, and RNA technologies targeting neuromuscular diseases.